These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 32667213

  • 1. Emerging drugs for the treatment of hidradenitis suppurativa.
    Folkes AS, Hawatmeh FZ, Wong A, Kerdel FA.
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
    [Abstract] [Full Text] [Related]

  • 2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I, Brkić J, Ćorluka M, Čović M, Pejić J, Zeljko Penavić J.
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
    Tzanetakou V, Stergianou D, Giamarellos-Bourboulis EJ.
    Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira HD.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1192-1196. PubMed ID: 27741335
    [Abstract] [Full Text] [Related]

  • 5. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
    Theut Riis P, Thorlacius LR, Jemec GB.
    Expert Opin Investig Drugs; 2018 Jan 01; 27(1):43-53. PubMed ID: 29188733
    [Abstract] [Full Text] [Related]

  • 6. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.
    Br J Dermatol; 2019 Nov 01; 181(5):967-975. PubMed ID: 30916379
    [Abstract] [Full Text] [Related]

  • 7. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
    Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N.
    Clin Pharmacokinet; 2017 Sep 01; 56(9):1091-1102. PubMed ID: 28066879
    [Abstract] [Full Text] [Related]

  • 8. Biologic Treatment for Hidradenitis Suppurativa.
    Flood KS, Porter ML, Kimball AB.
    Am J Clin Dermatol; 2019 Oct 01; 20(5):625-638. PubMed ID: 31140067
    [Abstract] [Full Text] [Related]

  • 9. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
    Holcomb ZE, Porter ML, Kimball AB.
    Expert Opin Drug Saf; 2021 Oct 01; 20(10):1147-1161. PubMed ID: 33910441
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES, Garnock-Jones KP, Keam SJ.
    Am J Clin Dermatol; 2016 Oct 01; 17(5):545-552. PubMed ID: 27665300
    [Abstract] [Full Text] [Related]

  • 11. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.
    Scheinfeld N.
    Dermatol Online J; 2013 Apr 15; 19(4):1. PubMed ID: 24021361
    [Abstract] [Full Text] [Related]

  • 12. Biologic therapies for the treatment of hidradenitis suppurativa.
    Rosales Santillan M, Morss PC, Porter ML, Kimball AB.
    Expert Opin Biol Ther; 2020 Jun 15; 20(6):621-633. PubMed ID: 32077334
    [Abstract] [Full Text] [Related]

  • 13. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V, Mrowietz U.
    J Dtsch Dermatol Ges; 2009 Feb 15; 7(2):139-41. PubMed ID: 19371236
    [Abstract] [Full Text] [Related]

  • 14. Use of biological treatments in patients with hidradenitis suppurativa.
    Martin-Ezquerra G, Masferrer E, Pujol RM.
    G Ital Dermatol Venereol; 2017 Aug 15; 152(4):373-378. PubMed ID: 27982551
    [Abstract] [Full Text] [Related]

  • 15. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E, Sapigni C, Campanati A, Brisigotti V, Offidani A.
    Expert Opin Drug Metab Toxicol; 2020 Nov 15; 16(11):1019-1037. PubMed ID: 32896186
    [Abstract] [Full Text] [Related]

  • 16. The pharmacology of antibiotic therapy in hidradenitis suppurativa.
    Marasca C, Tranchini P, Marino V, Annunziata MC, Napolitano M, Fattore D, Fabbrocini G.
    Expert Rev Clin Pharmacol; 2020 May 15; 13(5):521-530. PubMed ID: 32364806
    [Abstract] [Full Text] [Related]

  • 17. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
    Porter ML, Golbari NM, Lockwood SJ, Kimball AB.
    Semin Cutan Med Surg; 2018 Sep 15; 37(3):182-189. PubMed ID: 30215636
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F, Ghazavi M.
    Pharmacoeconomics; 2017 Aug 15; 35(8):805-815. PubMed ID: 28176188
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development.
    Westerkam L, Sayed C.
    J Drugs Dermatol; 2023 Oct 01; 22(10):1021-1026. PubMed ID: 37801538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.